Edwards Lifesciences/$EW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Ticker
$EW
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
15,800
ISIN
US28176E1082
Website
EW Metrics
BasicAdvanced
$43B
10.53
$7.02
1.13
-
Price and volume
Market cap
$43B
Beta
1.13
52-week high
$95.25
52-week low
$58.93
Average daily volume
4.1M
Financial strength
Current ratio
4.454
Quick ratio
3.334
Long term debt to equity
6.63
Total debt to equity
6.863
Interest coverage (TTM)
77.41%
Profitability
EBITDA (TTM)
1,686
Gross margin (TTM)
79.50%
Net profit margin (TTM)
75.71%
Operating margin (TTM)
27.75%
Effective tax rate (TTM)
10.93%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
8.42%
Return on equity (TTM)
16.51%
Valuation
Price to earnings (TTM)
10.532
Price to revenue (TTM)
7.958
Price to book
4.28
Price to tangible book (TTM)
6.04
Price to free cash flow (TTM)
70.528
Free cash flow yield (TTM)
1.42%
Free cash flow per share (TTM)
104.89%
Growth
Revenue change (TTM)
8.23%
Earnings per share change (TTM)
201.77%
3-year revenue growth (CAGR)
1.02%
10-year revenue growth (CAGR)
8.73%
3-year earnings per share growth (CAGR)
42.45%
10-year earnings per share growth (CAGR)
18.04%
What the Analysts think about EW
Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.
Bulls say / Bears say
Edwards Lifesciences' Surgical Structural Heart segment has shown promising growth, with a 5% increase in Q4 2024, driven by strong global adoption of premium surgical technologies like INSPIRIS, MITRIS, and KONECT. (nasdaq.com)
The company's Transcatheter Aortic Valve Replacement (TAVR) platform continues to lead globally, achieving a 5.3% year-over-year growth in Q4 2024, supported by the launch of SAPIEN 3 Ultra RESILIA in Europe. (nasdaq.com)
Edwards Lifesciences maintains a strong financial position with a solid balance sheet, holding $1.64 billion in cash and cash equivalents as of Q4 2023, and no near-term debt payable. (nasdaq.com)
The company faces macroeconomic challenges, including inflation and factors affecting economic stability, which could impact operating results. (nasdaq.com)
Foreign exchange headwinds have adversely affected Edwards Lifesciences' gross margin, with a 30 basis point decrease in Q4 2024 compared to the prior year. (nasdaq.com)
The medical technology industry is highly competitive, with Edwards Lifesciences facing significant competition in the TAVR market from companies like Medtronic, Abbott Laboratories, and Boston Scientific Corporation. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 29 May 2025.
EW Financial Performance
Revenues and expenses
EW Earnings Performance
Company profitability
EW News
AllArticlesVideos
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
Business Wire·4 weeks ago
Trade Tracker: Bill Baruch buys Edwards Lifesciences
CNBC Television·1 month ago
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Edwards Lifesciences stock?
Edwards Lifesciences (EW) has a market cap of $43B as of June 20, 2025.
What is the P/E ratio for Edwards Lifesciences stock?
The price to earnings (P/E) ratio for Edwards Lifesciences (EW) stock is 10.53 as of June 20, 2025.
Does Edwards Lifesciences stock pay dividends?
No, Edwards Lifesciences (EW) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Edwards Lifesciences dividend payment date?
Edwards Lifesciences (EW) stock does not pay dividends to its shareholders.
What is the beta indicator for Edwards Lifesciences?
Edwards Lifesciences (EW) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.